Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.

[1]  Deepak L. Bhatt,et al.  Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery , 2001, Circulation.

[2]  N. Shammas,et al.  Evidence-based management of peripheral vascular disease , 2005, Current atherosclerosis reports.

[3]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[4]  C. Sudlow,et al.  Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. , 2000, Stroke.

[5]  V. Basevi.  Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[6]  A. Jacobson.  Platelet ADP receptor antagonists: ticlopidine and clopidogrel. , 2004, Best practice & research. Clinical haematology.

[7]  I. Seong,et al.  Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). , 2008, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Circulation.

[9]  M. Pfeffer,et al.  Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. , 2004, Diabetes care.

[10]  G. Lip,et al.  Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[11]  G. Clagett,et al.  Antithrombotic therapy in peripheral arterial occlusive disease. , 1992, Chest.

[12]  N. Agrawal,et al.  Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. , 2007, Pharmacological research.

[13]  C. Lau,et al.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.

[14]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[15]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[16]  Deepak L. Bhatt,et al.  Aspirin and clopidogrel resistance: an emerging clinical entity. , 2006, European heart journal.

[17]  N. Tsushima,et al.  The Clinical Features and Treatment of Arteriosclerosis Obliterane With Diabetes , 1996, Diabetes.

[18]  Y. Yamasaki,et al.  The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial , 2010, Circulation.

[19]  Deepak L. Bhatt,et al.  Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. , 2000, American heart journal.

[20]  G. Ciuffetti,et al.  Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis. , 2001, Clinical hemorheology and microcirculation.

[21]  C. Grattan.  Aspirin sensitivity and urticaria , 2003, Clinical and experimental dermatology.

[22]  M. Creager.  Medical Management of Peripheral Arterial Disease , 2001, Cardiology in review.

[23]  A. Comerota,et al.  Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. , 2001, The American journal of cardiology.

[24]  Y. Loke,et al.  Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.

[25]  V. Fuster,et al.  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1997, Circulation.

[26]  E. Mohler.  Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines , 2007, Nature Clinical Practice Cardiovascular Medicine.

[27]  C. Jenkins,et al.  Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice , 2004, BMJ : British Medical Journal.